## Acarbose as an Irreversible Inhibitor of α-Glucosidase ### Clinical Context **Key Point:** Acarbose is an **irreversible (pseudo-irreversible / covalent) inhibitor** of α-glucosidase. It forms a stable, long-lived covalent intermediate with the enzyme's active site, meaning its inhibitory effect **cannot be overcome** by increasing substrate (carbohydrate) concentration — no matter how large the meal. ### Why Irreversible Covalent Binding Explains Acarbose's Efficacy **High-Yield:** In irreversible inhibition: - The inhibitor forms a **covalent bond** with a catalytic residue at the active site - Increasing substrate concentration does **not** displace the inhibitor - The enzyme is permanently inactivated for the duration of drug binding; activity is only restored by synthesis of new enzyme - This is distinct from competitive inhibition, where high substrate can outcompete the inhibitor ### Mechanism of Acarbose Action 1. Acarbose (a pseudo-tetrasaccharide) mimics the transition state of oligosaccharide hydrolysis 2. It forms a **covalent glycosyl-enzyme intermediate** with the catalytic nucleophile (Asp) of α-glucosidase — a mechanism confirmed by crystallographic and kinetic studies (Brayer et al.; Robyt & French) 3. This covalent intermediate is extremely stable (slow off-rate), effectively irreversible under physiological conditions 4. Even with a large carbohydrate meal (high [substrate]), the covalently inhibited enzyme cannot be displaced 5. Result: **Sustained delay of glucose absorption → blunted postprandial glycemia** ### Kinetic Comparison | Feature | Competitive Inhibitor | Irreversible (Acarbose) | |---|---|---| | **Binding** | Reversible, active site | Covalent, active site | | **Effect of high [S]** | Inhibition overcome | Inhibition **NOT** overcome | | **Vmax** | Unchanged (apparent) | Decreased (enzyme molecules inactivated) | | **Km** | Increases (apparent) | Not applicable | | **Clinical implication** | Efficacy reduced by large meal | Efficacy maintained regardless of meal size | ### Why the Other Options Are Incorrect - **Option B (non-competitive, decreases Vmax):** Acarbose binds at the **active site**, not an allosteric site. It is not a classical non-competitive inhibitor. While irreversible inhibition does reduce apparent Vmax (by reducing functional enzyme), the mechanism is covalent active-site binding, not allosteric. - **Option C (higher affinity than glucose):** Acarbose does have high affinity, but affinity alone (reversible tight binding) could theoretically be overcome at very high substrate concentrations; it is the **irreversibility** of binding that ensures the effect persists. - **Option D (competitive, increases Km):** Competitive inhibition is reversible and can be overcome by high substrate — the opposite of what the stem describes. ### Clinical Pearl **Why acarbose works despite high carbohydrate intake:** Because it forms a **covalent bond** with the enzyme's active site, the drug cannot be displaced by substrate molecules. The enzyme is functionally inactivated until new enzyme is synthesized. This irreversible mechanism is the pharmacokinetic basis for acarbose's consistent postprandial glucose-lowering effect. **Reference:** Lehninger Principles of Biochemistry (Nelson & Cox), Chapter on Enzyme Inhibition; KD Tripathi Essentials of Medical Pharmacology, Antidiabetic Drugs chapter.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.